a16z Podcast
Can we make science as fast as software?
In this episode, Erik Torenberg talks with Patrick Hsu (cofounder of Arc Institute) and a16z general partner Jorge Conde about Arc’s “virtual cells” moonshot, which uses foundation models to simulate biology and guide experiments.
They discuss why research is slow, what an AlphaFold-style moment for cell biology could look like, and how AI might improve drug discovery. The conversation also covers hype versus substance in AI for biology, clinical bottlenecks, capital intensity, and how breakthroughs like GLP-1s show the path from science to major business and health impact.
Resources:
Find Patrick on X: https://x.com/pdhsu
Find Jorge on X: https://x.com/JorgeCondeBio
Stay Updated:
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Podcast on Spotify
Listen to the a16z Podcast on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
-
When Medicine Goes Virtual
We’re at a moment where we are now seeing medicine go virtual faster, and at a scale that it has never done before. In this conversation, a16z bio general partners Vijay Pande and Julie Yoo, who come from the worlds…
-
Labs for Diagnostics: Then, Now, and Next
A lot’s going on in the world of healthcare right now, and one topic that’s especially relevant is how diagnostic labs work. In this episode with Dave King, Executive Chairman of Lab Corp (one of…
-
How a16z’s Crypto Startup School Went Remote
On February 21, Andreessen Horowitz kicked off its very first Crypto Startup School, with 45 students from around the U.S. and three countries gathering to learn how to build crypto projects. But just two weeks…
-
When Fintech Meets Social
The last financial crisis prompted many consumers to reassess their banking expectations—none more so than millennials and Gen-Z-ers. While revealing one’s financial information was once considered taboo, now consumers are more apt than ever to…
-
Innovation Through Software Development and IT
One of the recurring themes we talk about a lot on the a16z Podcast is how software changes organizations, and vice versa… More broadly: it’s really about how companies of all kinds innovate with the…
-
The Open Source CIO
In 2014, in “Why There Will Never Be Another Red Hat,” Peter Levine argued that Red Hat’s open source business model of commercializing support and services was highly difficult to replicate. Instead, he predicted the…
-
Novel Coronavirus Updates: How Healthcare System, Tests Work; More
This episode covers the following — since our previous deep-dive on the novel coronavirus outbreak — including: practical implications for the U.S. healthcare system given how it works today, and where we might go in…
-
Metrics and Mindsets for Retention & Engagement
It’s “Marketplaces Week” for us at a16z, thanks to our consumer team releasing a new index of the next industry-defining marketplaces, the Marketplace 100. But what happens as such marketplaces and other platforms evolve…
-
Tough Love, Global Diplomacy, and Lessons on Leadership
Susan shares how she learned to leverage the characteristics of her personality early in her career as assistant secretary of state [2:05] One of the important conversations Susan had with a mentor that changed the…
-
Building the First CAR T Company
with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousread CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential…